Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Denver-Aurora, CO MSA — October 2026
Denver life sciences vacancy tightens as regulatory pay slips.
Denver-Boulder life sciences vacancy fell 320 basis points to 23.8% even as advertised Regulatory Affairs pay dropped to $96,122, a gap that signals compensation strategy is lagging where talent scarcity is worst.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Denver-Boulder life sci vacancy: 23.8% — Down 320 bps year-over-year
- Metro unemployment rate: 4.6% — Denver-Aurora-Centennial, Aug 2026 (prelim)
- National biopharma quit rate: 1.9% — Signals talent staying despite hiring growth
- Colorado labor force participation: Lowest since 1976 — Ranks 43rd nationally, down 1.8 ppt YoY
Key takeaways
Regulatory Affairs pay fell while the role stayed hard to fill.
Metro advertised pay for Regulatory Affairs Specialist dropped significantly to $96,122, trailing the national median of $103,780, even as Colorado research describes regulatory affairs as facing some of the widest talent gaps with longer Q4 searches and more frequent counteroffers. Declining advertised rates alongside persistent scarcity may suggest employers are under-pricing a role candidates still have leverage to negotiate up once in process.
Clinical Research Associate pay is pulling away from the national trend.
Metro CRA advertised pay rose to $97,601, now running ahead of the $90,065 national median, consistent with national reporting that experienced CRAs are the bottleneck constraining clinical trial capacity, with entry-level hiring playing a smaller role in easing that constraint. Organizations relying on flat or historical CRA budgets risk losing ground against Denver-specific wage movement in a role tied directly to trial timelines.
Manufacturing-to-research pay gaps are widening internal equity risk.
Pharma and biotech manufacturing roles carry a median salary near $162,000 against roughly $108,390 for Research Scientist I positions statewide, a gap wide enough to strain internal equity narratives as manufacturing credentials grow scarcer. Compensation teams should examine whether R&D pay structures are keeping pace with manufacturing's premium before cross-functional mobility or retention conversations surface the disparity.
Aging workforce concentration raises succession stakes locally.
Nearly 25% of the national life sciences workforce is 55 or older, a demographic reality that compounds Denver's already-low labor force participation and 23.8% vacancy rate in lab and manufacturing talent. Succession planning for senior scientific and quality roles may need to move from a five-year horizon to an 18-24 month planning window given how thin the local replacement pipeline appears.
Median advertised pay by role — Denver-Aurora, CO MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $95,813 | $116,022 | $143,357 | Moderate increase | $130,339 |
| Clinical Research Associate | $70,262 | $97,601 | $106,700 | Significant increase | $90,065 |
| Lab Technician | $42,990 | $50,918 | $52,287 | Moderate increase | $47,840 |
| Regulatory Affairs Specialist | $73,388 | $96,122 | $116,373 | Significant decline | $103,780 |
| Clinical Data Manager | $98,014 | $126,230 | $146,400 | Stable | $123,653 |
| Biostatistician | $111,745 | $131,971 | $158,127 | Stable | $131,958 |
| Validation Engineer | $97,139 | $111,831 | $165,360 | Stable | $106,478 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Denver-Boulder life sciences vacancy compressed 320 basis points year-over-year to 23.8%, tightening available lab and manufacturing talent even as metro unemployment edged up to 4.6% in August and statewide labor force participation hit its lowest level since 1976. National biopharma hiring has rebounded sharply — Q3 layoffs fell 90% year-over-year with 64% of organizations actively recruiting — but the national quit rate holds at 1.9%, meaning Denver employers are competing for a candidate pool that is both shrinking and reluctant to move.
What it means
Falling labor force participation combined with a 23.8% life sciences vacancy rate means Denver employers cannot assume a deep local bench for regulatory affairs, clinical operations, or GMP-credentialed manufacturing roles — the same functions flagged nationally as hardest to fill in 2026. KBI Biopharma's extension of its commercial manufacturing agreement through 2029 signals that committed in-house capacity remains viable locally even as CDMOs nationally compete for the same scarce bioprocess expertise, sharpening the build-vs-outsource calculus for mid-size biotech and device firms. Consider stress-testing headcount plans against realistic time-to-fill assumptions for regulatory and manufacturing roles, given how far candidate supply has diverged from hiring intent and how quickly historical benchmarks can become outdated.
Looking ahead
Early indicator: Colorado's $2.2M in Advanced Industries funding for gene therapy and cell/gene manufacturing platforms could seed new hiring activity in Denver's biomanufacturing segment over the next two quarters. Watch whether funded recipients begin advertising for process development and validation roles, a leading signal for where scarce GMP talent gets bid up next.
Worth watching: Colorado's September unemployment tick to 4.1% and falling labor force participation have not yet shown up as softer life sciences vacancy; if anything the sector's vacancy rate moved the opposite direction. A divergence this pronounced is worth tracking into the November 20 state labor release to see whether broader softening eventually reaches scientific and regulatory hiring.
Emerging pressure point: National quit rates sitting at 1.9% suggest experienced regulatory, clinical operations, and CMC talent are staying in their current roles even with 41% of biopharma organizations expecting more open roles in 2026. Expect counteroffer activity and internal promotion-in-lieu-of-hire to intensify as Denver employers compete for a pool that is holding steady rather than growing.
Potential inflection point: KBI Biopharma's multi-year manufacturing commitment and continued CDMO competition for bioprocess expertise point to a widening gap between companies with locked-in manufacturing capacity and those still negotiating outsourcing terms. Firms without long-term CDMO agreements may find 2027 capacity and pricing less favorable if scarcity persists through year-end.
Sources
- Colorado Life Sciences Labor Market Research, October 2026 — Denver-Boulder life sciences vacancy declined 320 bps YoY to 23.8%
- Bureau of Labor Statistics / Metro Denver conditions research — Denver-Aurora-Centennial metro unemployment at 4.6% in August 2026
- National Life Sciences Labor Market Research, October 2026 — Q3 biopharma layoffs down 90% YoY, 64% actively recruiting
- Colorado Life Sciences Labor Market Research, October 2026 — KBI Biopharma extended commercial manufacturing agreements through 2029
- Colorado Life Sciences Labor Market Research, October 2026 — Pharma/biotech manufacturing median salary ~$162,000 vs Research Scientist I ~$108,390
- Colorado Life Sciences Labor Market Research, October 2026 — Colorado labor force participation fell 1.8 ppt YoY, ranking 43rd nationally
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.